Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

Chloé James, Valérie Ugo, Jean‐Pierre Le Couedic et al. · Nature · 2005 · 3.5K citations

Hematological Malignancy, Signal Transduction, Receptor Tyrosine Kinase +9

A Gain-of-Function Mutation of <i>JAK2</i> in Myeloproliferative Disorders

Róbert Královics, Francesco Passamonti, Andreas Buser et al. · New England Journal of Medicine · 2005 · 3.4K citations · Full text

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

E. Joanna Baxter, Linda M. Scott, Peter J. Campbell et al. · The Lancet · 2005 · 3.4K citations

Hematological Malignancy, Acquired Mutation, Receptor Tyrosine Kinase +9

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

Ross L. Levine, Martha Wadleigh, Jan Cools et al. · Cancer Cell · 2005 · 3K citations · Full text

Hematological Malignancy, Polycythemia Vera, Essential Thrombocythemia +11

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

Ayalew Tefferi, Jüergen Thiele, Attilio Orazi et al. · Blood · 2007 · 857 citations · Full text